Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$0.4 - $0.56 $328 - $460
-822 Reduced 30.3%
1,891 $0
Q1 2024

May 10, 2024

BUY
$0.53 - $1.89 $368 - $1,315
696 Added 34.51%
2,713 $1,000
Q4 2023

Feb 09, 2024

BUY
$1.22 - $5.24 $2,429 - $10,432
1,991 Added 7657.69%
2,017 $2,000
Q3 2023

Nov 09, 2023

SELL
$2.75 - $5.17 $2,645 - $4,973
-962 Reduced 97.37%
26 $0
Q2 2023

Aug 10, 2023

SELL
$4.09 - $8.29 $6,437 - $13,048
-1,574 Reduced 61.44%
988 $4,000
Q1 2023

May 11, 2023

BUY
$4.89 - $10.53 $2,063 - $4,443
422 Added 19.72%
2,562 $20,000
Q4 2022

Feb 09, 2023

BUY
$3.86 - $42.0 $8,260 - $89,880
2,140 New
2,140 $16,000

Others Institutions Holding BIVI

About BIOVIE INC.


  • Ticker BIVI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,165,300
  • Market Cap $64.3M
  • Description
  • BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial ...
More about BIVI
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.